Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio

J Gastroenterol Hepatol. 2011 Jan;26(1):49-54. doi: 10.1111/j.1440-1746.2010.06489.x.

Abstract

Background and aim: Allopurinol potentiates azathioprine and 6-mercaptopurine (6-MP) by increasing 6-thioguanine nucleotide (6-TGN) metabolite concentrations. The outcome might also be improved by adding allopurinol in individuals who preferentially produce 6-methylmercaptopurine nucleotides (6-MMPN), rather than 6-TGN. The aim of the present study was to investigate the effect of allopurinol on concentrations of 6-MMPN and 6-TGN in individuals with a high ratio of these metabolites (>20), which is indicative of a poor thiopurine response.

Methods: Sixteen individuals were identified who were taking azathioprine or 6-MP, and were commenced on allopurinol to improve a high 6-MMPN:TGN ratio. Metabolite concentrations were compared before and after commencing allopurinol, and markers of disease control were compared.

Results: The addition of 100-300 mg allopurinol daily and thiopurine dose reduction (17-50% of the original dose) resulted in a reduction of the median (and range) 6-MMPN concentration, from 11,643 (3,365-27,832) to 221 (55-844) pmol/8×10(8) red blood cells (RBC; P=0.0005), increased 6-TGN from 162 (125-300) to 332 (135-923) pmol/8×10(8) RBC (P=0.0005), and reduced the 6-MMPN:6-TGN ratio from 63 (12-199) to 1 (0.1-4.5) (P=0.0005). There was a significant reduction in steroid dose requirements at 12 months (P=0.04) and trends for improvement in other markers of disease control. One patient developed red cell aplasia that resolved upon stopping azathioprine and allopurinol.

Conclusions: In those with a high 6-MMPN:6-TGN ratio (>20), response to thiopurine treatment might be improved by the addition of allopurinol, together with a reduced thiopurine dose and close hematological monitoring.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Allopurinol / adverse effects
  • Allopurinol / therapeutic use*
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / therapeutic use*
  • Azathioprine / adverse effects
  • Azathioprine / pharmacokinetics
  • Azathioprine / therapeutic use*
  • Biotransformation
  • Drug Therapy, Combination
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use*
  • Erythrocyte Count
  • Female
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / pharmacokinetics
  • Gastrointestinal Agents / therapeutic use*
  • Guanine Nucleotides / blood
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / enzymology
  • Male
  • Mercaptopurine / adverse effects
  • Mercaptopurine / pharmacokinetics
  • Mercaptopurine / therapeutic use*
  • Middle Aged
  • New Zealand
  • Red-Cell Aplasia, Pure / blood
  • Red-Cell Aplasia, Pure / chemically induced
  • Retrospective Studies
  • Steroids / therapeutic use
  • Thionucleotides / blood
  • Time Factors
  • Treatment Outcome
  • Xanthine Oxidase / antagonists & inhibitors*
  • Xanthine Oxidase / metabolism

Substances

  • Anti-Inflammatory Agents
  • Enzyme Inhibitors
  • Gastrointestinal Agents
  • Guanine Nucleotides
  • Steroids
  • Thionucleotides
  • 6-thioguanylic acid
  • Allopurinol
  • Mercaptopurine
  • Xanthine Oxidase
  • Azathioprine